Clinical trial
Immunogenicity and Safety of Inactivated COVID-19 Vaccine Coadministered With 23-valent Pneumococcal Polysaccharide Vaccine and Quadrivalent Influenza Vaccine in Hemodialysis Population: a Multicentre, Randomised, Controlled, Phase 4 Trial
NCT05480436 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of Inactivated COVID-19 Vaccine Coadministered With 23-valent Pneumococcal Polysaccharide Vaccine and Quadrivalent Influenza Vaccine in Hemodialysis Population: a Multicentre, Randomised, Controlled, Phase 4 Trial
- Lead sponsor
- China National Biotec Group Company Limited
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- August 5, 2022
- Completion date
- July 30, 2023
- Enrollment
- 1,200 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.